Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment

Ann Oncol. 2017 Dec 1;28(12):3108. doi: 10.1093/annonc/mdx531.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects*
  • Carcinoma, Acinar Cell / drug therapy
  • Carcinoma, Acinar Cell / radiotherapy
  • Carcinoma, Acinar Cell / surgery
  • Female
  • Humans
  • Parotid Neoplasms / drug therapy
  • Parotid Neoplasms / radiotherapy
  • Parotid Neoplasms / surgery
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Programmed Cell Death 1 Receptor / immunology
  • Sjogren's Syndrome / chemically induced*
  • Sjogren's Syndrome / immunology

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • pembrolizumab